Harrow Aktie - HROW

Q: What is the current Harrow share price?

The current share price of Harrow is US$ 23,32

Q: How many Harrow shares are in issue?

Harrow has 35.614.718 shares in issue

Q: What is the market cap of Harrow?

The market capitalisation of Harrow is USD 830,54M

Q: What is the 1 year trading range for Harrow share price?

Harrow has traded in the range of US$ 9,30 to US$ 59,23 during the past year

Q: What is the PE ratio of Harrow?

The price to earnings ratio of Harrow is -39,25

Q: What is the cash to sales ratio of Harrow?

The cash to sales ratio of Harrow is 7,36

Q: What is the reporting currency for Harrow?

Harrow reports financial results in USD

Q: What is the latest annual turnover for Harrow?

The latest annual turnover of Harrow is USD 130,19M

Q: What is the latest annual profit for Harrow?

The latest annual profit of Harrow is USD -24,41M

Q: What is the registered address of Harrow?

The registered address for Harrow is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

23,32

Gebot

26,75

Fragen

27,00

Volumen

0,00 Tagesbereich 0,00

9,30 52-Wochen-Bereich 59,23

Marktkapitalisierung

830,535M

Handelsende

23,32

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

356.263

Ausgegebene Aktien

35.614.718

Dividendenrendite

Kurs-Gewinn-Verhältnis

-39,25

Gewinn pro Aktie (EPS)

-0,69

Erlöse

130,19M

Nettogewinn

-24,41M

Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Drople... Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.harrow.com

Hauptsitz

Dover, Delaware, USA

Gegründet

Harrow Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HROW. The last closing price for Harrow was US$23,32. Over the last year, Harrow shares have traded in a share price range of US$ 9,30 to US$ 59,23.

Harrow currently has 35.614.718 shares in issue. The market capitalisation of Harrow is US$830,54 million. Harrow has a price to earnings ratio (PE ratio) of -39.25.

Gesamtfluss

Bärisch

Nettoprämie

-1M

Calls / Puts

33,33%

Käuf. / Verkä.

33,33%

OTM / ITM

33,33%

Sweeps

0,00%

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Company Expects to Provide Revised Dates for Release of Audited Financial Results, Conference Call, and Letter to Stockholders Harrow (Nasdaq:...

Harrow Launches VEVYE® Access for All

Groundbreaking Access Program to Reduce Patient Barriers to Dry Eye Disease Therapy Harrow (Nasdaq: HROW), a leading North American eyecare...

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 18, 2025 Harrow (Nasdaq: HROW), a leading North American...

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through...

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined...

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Jury in Trademark Infringement Case Finds in Favor of ImprimisRx Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company...

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P<0.001) for Providing Successful...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.98	4.38675022381	22.34	28.35	21.69	524085	22.94597243	CS
4	-7.23	-23.6661211129	30.55	31.54	21.14	413429	25.46388477	CS
12	-10.35	-30.7395307395	33.67	37.47	21.14	356263	29.79740796	CS
26	-20.01	-46.1804754212	43.33	59.23	21.14	446022	40.01544978	CS
52	12.88	123.37164751	10.44	59.23	9.3	498362	30.50608013	CS
156	16.06	221.212121212	7.26	59.23	5.4	403450	21.17456717	CS
260	19.69	542.424242424	3.63	59.23	3.33	308436	18.17220875	CS

HROW - Frequently Asked Questions (FAQ)

What is the current Harrow share price?

The current share price of Harrow is US$ 23,32

How many Harrow shares are in issue?

Harrow has 35.614.718 shares in issue

What is the market cap of Harrow?

The market capitalisation of Harrow is USD 830,54M

What is the 1 year trading range for Harrow share price?

Harrow has traded in the range of US$ 9,30 to US$ 59,23 during the past year

What is the PE ratio of Harrow?

The price to earnings ratio of Harrow is -39,25

What is the cash to sales ratio of Harrow?

The cash to sales ratio of Harrow is 7,36

What is the reporting currency for Harrow?

Harrow reports financial results in USD

What is the latest annual turnover for Harrow?

The latest annual turnover of Harrow is USD 130,19M

What is the latest annual profit for Harrow?

The latest annual profit of Harrow is USD -24,41M

What is the registered address of Harrow?

The registered address for Harrow is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904

What is the Harrow website address?

The website address for Harrow is www.harrow.com

Which industry sector does Harrow operate in?

Harrow operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AAGRAfrican Agriculture Holdings Inc	US$ 0,1326 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 78,3889 (0,00%)	0
AADIAadi Bioscience Inc	US$ 2,10 (0,00%)	0
AACGATA Creativity Global	US$ 0,85 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 10,05 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,1326 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 78,3889 (0,00%)	0
AADIAadi Bioscience Inc	US$ 2,10 (0,00%)	0
AACGATA Creativity Global	US$ 0,85 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 10,05 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,1326 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 78,3889 (0,00%)	0
AADIAadi Bioscience Inc	US$ 2,10 (0,00%)	0
AACGATA Creativity Global	US$ 0,85 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 10,05 (0,00%)	0

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Harrow Inc (HROW) Börsenkurse

Harrow Inc (HROW)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Harrow Inc

Option-Flow Harrow (HROW)

Gesamtfluss

Bärisch

Nettoprämie

-1M

Calls / Puts

33,33%

Käuf. / Verkä.

33,33%

OTM / ITM

33,33%

Sweeps

0,00%

HROW Neueste Nachrichten

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Harrow Announces Participation in Upcoming Investor Conferences

Harrow Announces Third Quarter 2024 Financial Results

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Harrow Announces Participation in Upcoming Investor Conferences

HROW - Frequently Asked Questions (FAQ)

Beweger

HROW Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen